ASP7374: Phase III ongoing

Astellas and UMN Pharma said all subjects were vaccinated in a double-blind, Japanese Phase III trial comparing subcutaneous ASP7374 vs. an approved egg-derived trivalent inactivated vaccine. The trial planned to enroll 900 healthy volunteers 20-64 years of age. Both companies declined to disclose the number of subjects enrolled. ...